---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041982"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:18:14.590413+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics announces registered direct offering of 1.14M shares at $0.64/share, with warrants

## Summary
- Gross proceeds ~$729,200; net proceeds ~$591,000 after fees.
- Warrants to purchase up to 1,139,063 shares at $0.52/exercise, 5.5-year term.
- H.C. Wainwright acts as placement agent; fees: 7% cash, 1% mgmt, 68,344 warrants.
- Closing expected Nov 20, 2023; proceeds for clinical trials, patent portfolio, working capital.

## SEC filing metadata
- accession: 0001493152-23-041982
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315223041982/0001493152-23-041982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315223041982/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041982
- JSON: https://secwatch.observer/filing/0001493152-23-041982.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041982.txt

## Key facts
- Material Agreements
  Bone Biologics Corp entered into Purchase Agreement with certain institutional investors valued at 1,139,063 shares of the Company's common stock, $0.001 par value per share, at an offering price of (effective 2023-11-16).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: 1,139,063 shares of the Company's common stock, $0.001 par value per share, at an offering price of
  - Effective: 2023-11-16
  source text: On November 16, 2023, Bone Biologics Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Registered Direct Offering”), 1,139,063 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at an offering price of $0.64 per Share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419554/000149315223041982/0001493152-23-041982-index.htm
- Material Agreements
  Bone Biologics Corp entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering and a management fee (effective 2023-10-30).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering and a management fee
  - Effective: 2023-10-30
  source text: On October 30, 2023, the Company entered into an engagement agreement (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the exclusive placement agent in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419554/000149315223041982/0001493152-23-041982-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.